FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896636974> ?p ?o ?g. }

• W2896636974 endingPage "e94" @default.
• W2896636974 startingPage "e94" @default.
• W2896636974 abstract "The present work aims to evaluate the safety and efficacy of partial stereotactic ablative boost radiotherapy (P-SABR) in bulky bladder and urothelial cancer and prove that P-SABR could optimize BED with equivalent toxicity. From January 2013 through August 2017, 17 patients with bulky bladder and urothelial cancer treated with P-SABR technique were analyzed. The P-SABR plan consisted of one partial SABR plan (5-8 Gy/f, 3-5 fractions) to gross tumor boost (GTVb) followed by one conventional plan to the planning target volume (PTV). GTVb was the max volume receiving SABR to guarantee the PTV margin dose falloff to about 3 Gy/f. The total dose of PTV margin was planned to about 55 Gy. The simply CRT plans were created using the same planning parameters as the original plan, with the goal to achieve comparable organs-at-risks (OARs) doses and PTV margin dose to P-SABR plan. Dosimetric variables were acquired in both P-SABR and compared CRT plans. Toxicity, local control, and survival were also evaluated. Nine patients (52.9%) were male, and 8 patients (47.1%) were female. Median age at treatment was 66 years (46 to 84 years). Fourteen (82.3%) patients were pathologically diagnosed as urothelial cancer, 1 (5.9%) was SCC, and 2 (11.8%) were other types. Two patients (11.8%) had stage IV, 13 patients (76.5%) were recurrent after surgery and 2 (11.8%) were metastases after surgery. Median volume of the tumor treated by P-SABR was 164.69 cm3 (54.776 to 409.608 cm3) with a median maximal diameter of 8.59 cm (4.04 to 19.54 cm). Median follow up-was 11.9 months (range 2.7-39.8 months). No severe acute side effects >CTCAE Grade III were observed. One-year overall survival was 84.4%. Two-year overall survival was 47.5%. Two patients (11.8%) had CR, 5 patients (29.4%) had PR, 4 patients (23.5%) had SD, and 6 patients (35.3%) had PD (all achieved local response but systemic progression). Two-year local control rate was 100%. P-SABR had significantly higher HI index (p<0.05), while the similar CI index (p > 0.1). No differences were found in Dmin and D98 of PTV between P-SABR and the simply CRT plans (p > 0.1). Compared to the conventional plan, P-SABR plans increased dose at the isocenter, BED at the isocenter, Dmean and Dmax by 18.9%, 27.1%, 11.9%, and 18.1%, respectively (p < 0.001). We define B80 as the ration of volume of BED >80 Gy to the in-field tumor. B80, B90, B100, B110, V65, V70, and V75 were improved by 57.0%, 100%, 100%, 100%, 73.4%, 99.6%, and 100% in P-SABR plan (p < 0.05). P-SABR is feasible and well tolerated in bulky bladder and urothelial cancer. Local control rate is encouraging, which may due to the ability of P-SABR to optimize BED with equivalent toxicity." @default.
• W2896636974 created "2018-10-26" @default.
• W2896636974 creator A5019158636 @default.
• W2896636974 creator A5034495767 @default.
• W2896636974 creator A5036045996 @default.
• W2896636974 creator A5051891450 @default.
• W2896636974 creator A5090547095 @default.
• W2896636974 date "2018-11-01" @default.
• W2896636974 modified "2023-09-24" @default.
• W2896636974 title "Partial Stereotactic Ablative Boost Radiation Therapy in Bulky Bladder/Urothelial Cancer" @default.
• W2896636974 doi "https://doi.org/10.1016/j.ijrobp.2018.07.367" @default.
• W2896636974 hasPublicationYear "2018" @default.
• W2896636974 type Work @default.
• W2896636974 sameAs 2896636974 @default.
• W2896636974 citedByCount "0" @default.
• W2896636974 crossrefType "journal-article" @default.
• W2896636974 hasAuthorship W2896636974A5019158636 @default.
• W2896636974 hasAuthorship W2896636974A5034495767 @default.
• W2896636974 hasAuthorship W2896636974A5036045996 @default.
• W2896636974 hasAuthorship W2896636974A5051891450 @default.
• W2896636974 hasAuthorship W2896636974A5090547095 @default.
• W2896636974 hasConcept C106159729 @default.
• W2896636974 hasConcept C121608353 @default.
• W2896636974 hasConcept C126322002 @default.
• W2896636974 hasConcept C126838900 @default.
• W2896636974 hasConcept C126894567 @default.
• W2896636974 hasConcept C162324750 @default.
• W2896636974 hasConcept C187625094 @default.
• W2896636974 hasConcept C19617505 @default.
• W2896636974 hasConcept C201645570 @default.
• W2896636974 hasConcept C2776017024 @default.
• W2896636974 hasConcept C2989005 @default.
• W2896636974 hasConcept C509974204 @default.
• W2896636974 hasConcept C71924100 @default.
• W2896636974 hasConcept C85393063 @default.
• W2896636974 hasConcept C91602232 @default.
• W2896636974 hasConceptScore W2896636974C106159729 @default.
• W2896636974 hasConceptScore W2896636974C121608353 @default.
• W2896636974 hasConceptScore W2896636974C126322002 @default.
• W2896636974 hasConceptScore W2896636974C126838900 @default.
• W2896636974 hasConceptScore W2896636974C126894567 @default.
• W2896636974 hasConceptScore W2896636974C162324750 @default.
• W2896636974 hasConceptScore W2896636974C187625094 @default.
• W2896636974 hasConceptScore W2896636974C19617505 @default.
• W2896636974 hasConceptScore W2896636974C201645570 @default.
• W2896636974 hasConceptScore W2896636974C2776017024 @default.
• W2896636974 hasConceptScore W2896636974C2989005 @default.
• W2896636974 hasConceptScore W2896636974C509974204 @default.
• W2896636974 hasConceptScore W2896636974C71924100 @default.
• W2896636974 hasConceptScore W2896636974C85393063 @default.
• W2896636974 hasConceptScore W2896636974C91602232 @default.
• W2896636974 hasIssue "3" @default.
• W2896636974 hasLocation W28966369741 @default.
• W2896636974 hasOpenAccess W2896636974 @default.
• W2896636974 hasPrimaryLocation W28966369741 @default.
• W2896636974 hasRelatedWork W1497156168 @default.
• W2896636974 hasRelatedWork W2014519582 @default.
• W2896636974 hasRelatedWork W2072660622 @default.
• W2896636974 hasRelatedWork W2081883849 @default.
• W2896636974 hasRelatedWork W2113135498 @default.
• W2896636974 hasRelatedWork W2150598577 @default.
• W2896636974 hasRelatedWork W2284937652 @default.
• W2896636974 hasRelatedWork W3157286423 @default.
• W2896636974 hasRelatedWork W3209946730 @default.
• W2896636974 hasRelatedWork W2777338963 @default.
• W2896636974 hasVolume "102" @default.
• W2896636974 isParatext "false" @default.
• W2896636974 isRetracted "false" @default.
• W2896636974 magId "2896636974" @default.
• W2896636974 workType "article" @default.